Thank you!
Your support is sustaining the future of local news in our communities.

Study focus: treatment of dementia

Of all the diseases that afflict us, dementia is one of the most terrifying because we see it coming and it is inexorable. It takes the mind but leaves the body. We have theories about what causes Alzheimer’s disease — tangles of a protein called beta-amyloid and over-expression of another protein called tau. These proteins in altered forms were thought to be a cause but removing them from most of the cells in the brain using monoclonal antibodies, did not improve symptoms by much. Perhaps the intervention was too late. Both proteins are probably involved but neither has been a fertile source of treatments, and most clinical trials have failed.

I worked in a Department of Pathology and Cell Biology at Columbia University Irving Medical Center where there are basic scientists and pathologists. A pathologist friend lamented the lack of progress for dementia and Parkinsonism as professionally embarrassing. Heart disease, inflammatory diseases, diabetes, cancer, and other conditions have fared better; there are new and effective treatments to extend life and restore independence, most stemming from basic research in cell biology.

There are many cures offered on the internet, but most are wishful thinking or fraud. One study bears watching: it suggested that vaccination for shingles, a painful rash caused by lingering chickenpox virus (Herpes zoster), reduces the number of cases of dementia in older people. Herpes zoster is a neurotropic virus, that selectively infects nerve cells, whose connections, or synapses in the parts of the brain dedicated to memory are the cellular basis of memory. Each nerve cell has 10,000 or more connections with other neurons.

The study in question hangs on a decision made by the UK’s National Health Service after the Shingrix vaccine became available in 2013. NHS decided to give the vaccine to people in Wales born after Sept. 1, 1933, but not to those born one week before. The two groups, in Wales, 80 years old in 2013, were otherwise identical.Each part of the study had thousands of patients.

The chickenpox vaccine reduced the number of people who became demented over the next 7 years by about 20%. The paper is from scientists at Stanford and several Swiss and German universities. It is tough statistical sledding to read but the data are serious. Twenty percent of patients is too few to be confident, but too many to ignore. See below for the reference.

There are many cures offered on the internet, but most are wishful thinking or fraud.

This experiment has been repeated by combining other data from England and Wales. This type of analysis, involving thousands of patient records, has become possible by keeping records in searchable databases. Other versions of the chickenpox vaccine experiment use a more effective vaccine that became available in 2023. Does the newer vaccine protect better than 20%?Does a vaccine applied when people are younger, or given repeatedly, slow the onset of dementia even better?

Think of a slow acting virus that destroys or inhibits neurons or the synapses involved in memory.It could be Herpes zoster lingering from childhood chickenpox or another virus. The vaccine could induce antibodies and T cells that would stop the progression of the slow virus and stave off dementia.A viral cause of dementia would be extraordinary. And actionable.

A second discovery that may be helpful is the effect of weight loss drugs like Wegovy on dementia. These drugs may also help a number of problems including drug addiction and alcohol abuse.

There are several ways to study the effect of these remarkable drugs. One takes advantage of the fact that loss of brain volume is amarker of Alzheimer’s disease. As the disease progresses damage spreads through the brain and it shrinks, which can be observed by magnetic resonance imaging.

One placebo-controlled trial analyzed 204 patients with mild Alzheimer’s disease at 24 clinics in the United Kingdom. Before the study began, all patients had magnetic resonance imaging of their brains to evaluate structure and volume. Half were given a daily injection of 1.8 milligrams of liraglutide/day, a drug used in weight loss and diabetes, while an equal number received a placebo.Those who received liraglutide lost less brain volume (about 50%) than untreated patients. Cognitive testing was done at 0, 24, and 52 weeks and researchers found that patients who received liraglutide hada slower decline in cognitive function — halfthat of untreated patients. They also said they felt better.

Like the Herpes zoster study the results are not conclusive but at this stage we are looking for a new approach, not miracles. Liraglutide and other GLP-1 analogues are licensed for obesity and diabetes, so its path to treatment for Alzheimer’sand other dementias could be relatively swift.

Two independent and larger phase 3 trials are underway, with results due at the end of 2025. If the results are correct, oneprediction would be that people who had been on weight loss drugs should not be entering memory care units. That analysis is difficult, and some of the databases are proprietary, but we will follow these experiments.


To join a study, go to clinicaltrials.gov. Use the search function.


A natural experiment on the effect of herpes zoster vaccination on dementia

https://doi.org/10.1038/s41586-025-08800-x


Dementia symptoms and areas of the brain

https://www.alzheimers.org.uk/about-dementia/stage...


Evaluation of Novel GLP-1 analogue in the treatment of Alzheimer’s disease

Authors: Paul Edison et al.

Volume: Volume20, IssueS6

DOI: https://doi.org/10.1002/alz.089799

Published: 09 January 2025

PDF: https://alz-journals.onlinelibrary.wiley.com/doi/p....…

Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue licensed for the treatment of type 2 diabetes mellitus (T2DM). Preclinical evidence in transgenic models of Alzheimer’s disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers.

Richard Kessin, PhD is Emeritus Professor of Pathology and Cell Biology at the Columbia University Irving Medical Center.

The views expressed here are not necessarily those of The Lakeville Journal and The Journal does not support or oppose candidates for public office.

Latest News

HVRHS Announces Senior Awards

HVRHS Announces Senior Awards

Senior awards for the HVRHS Class of 2026 have been announced.

Nathan Miller

The Housatonic Valley Regional High School senior awards were announced for the Class of 2026. The graduation ceremony was held Friday, June 19. Student speakers acknowledged the importance of community, as several reflected on overcoming significant adversity in their young lives.

Norma Lake Award - Shanaya Duprey

Keep ReadingShow less

The nature of Upstate Art Weekend

The nature of Upstate Art Weekend
Opening of Upstate Art Weekend at Olana with Helen Toomer, Ellen Harvey, Jean Shin and Gabriela Salazar
D.H. Callahan

On Thursday, June 25, a collection of eager art enthusiasts gathered at Olana State Historic Estate in Hudson to kick off the seventh annual Upstate Art Weekend (UAW).

Helen Toomer, founder, was joined by sculptors Ellen Harvey, Jean Shin and Gabriela Salazar to discuss their work and the legacy of painter Frederic Church. Church, whose 200th birthday is being celebrated this year, is widely credited as one of the founding members of the Hudson River School of painting. The discussion took place at Olana, Church’s grand estate, where the three artists’ installations are on view.

Keep ReadingShow less
Benjamin Reynaert and the art of layered living

Benjamin Reynaert

Jennifer Almquist
Creating a home is, at its core, an act of love.
— Benjamin Reynaert

Benjamin Reynaert is focused on creative direction and interior styling. He is market director at Elle Décor, a design consultant, and author of “The Layered Home: Inspiration for Crafting Cozy, Collected Rooms,” published this year by Clarkson Potter. He co-founded Ticking Tent, a market featuring antiques, luxury items and vintage treasures. The biannual event is held in New Preston, Connecticut, and Bedford, New York.

Adopted from South Korea at 3 months old, Reynaert grew up in Bloomfield Hills, Michigan. He always knew he wanted to be an artist. “I just loved drawing. I loved making things with clay,” he said. “Remembering what it felt like to be creative as kids and applying that to our creativity as adults is essential.” A graduate of the Rhode Island School of Design (RISD), where he earned a BFA and a degree in architecture, Reynaert also studied bookbinding in Rome. His attention to detail and aesthetic sense reflect years of training and a finely tuned eye for objects. “Attending RISD nurtured my creativity and taught me how to problem-solve,” he said.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

Beneath the surface: Delano Dunn and Mickalene Thomas explore history, memory and art

Mickalene Thomas and Delano Dunn at Wassaic Project.

Lucia Landolo

Before “Echoes in the Margin,” Delano Dunn’s new solo exhibition at Troutbeck in Amenia opened, the artist sat down with curator and artist Mickalene Thomas for a conversation at the Wassaic Project on Wednesday, June 24. Their wide-ranging discussion offered an intimate look into Dunn’s practice while situating the work within broader questions of history, memory and representation.

Presented by the Wassaic Project, the exhibition brings Dunn’s richly layered paintings into conversation with Troutbeck itself, the historic estate long associated with artists, writers and civil rights leaders, including W.E.B. Du Bois, Langston Hughes and many more.

Keep ReadingShow less
Local performer Vemilo transforms the Moviehouse

Vemilo performs at the Moviehouse in Millerton.

D.H. Callahan

On Friday, June 26, patrons at the Moviehouse in Millerton were treated to a performance by local artist and musician Vemilo, who returned to the theater’s biggest room for a second full-length show.

Regular patrons will know Theatre Three as the setting for post-screening interviews, Q&As, discussions and the theater’s monthly movie trivia night. Vemilo’s performance entirely reimagined the space. With just a few props and pieces of furniture, the stage was transformed into Vemilo’s sanctuary.

Keep ReadingShow less
After a Hollywood career, Scott Siegler turns failure into fiction

Scott Siegler at his home in Sharon.

D.H. Callahan

Scott Siegler is bored of success stories. But Scott Siegler has had the kind of successful Hollywood career that people write books about.

Before he was 30, he’d earned three degrees. Before he moved to Hollywood, he’d already won an Emmy for one of the nine documentaries he directed and produced. Before he helped launch Netscape, bringing the Internet to the public, he’d already started his own Hollywood studio.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.